Generation Bio Co. (NASDAQ:GBIO) Short Interest Update

Generation Bio Co. (NASDAQ:GBIO) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,680,000 shares, a decrease of 34.4% from the February 28th total of 2,560,000 shares. Currently, 3.7% of the shares of the stock are short sold. Based on an average trading volume of 540,400 shares, the short-interest ratio is presently 3.1 days.

Insider Activity

In other Generation Bio news, Director Anthony G. Quinn purchased 125,791 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were bought at an average price of $0.96 per share, for a total transaction of $120,759.36. Following the completion of the acquisition, the director now owns 214,286 shares in the company, valued at approximately $205,714.56. This trade represents a 142.14 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 21.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Generation Bio

Hedge funds and other institutional investors have recently made changes to their positions in the business. Aegis Wealth Management LLC bought a new stake in Generation Bio during the 4th quarter worth approximately $94,000. Jefferies Financial Group Inc. purchased a new stake in Generation Bio in the 4th quarter valued at $2,398,000. Squarepoint Ops LLC bought a new position in Generation Bio during the 4th quarter valued at $70,000. Millennium Management LLC purchased a new position in Generation Bio during the 4th quarter worth $97,000. Finally, Jacobs Levy Equity Management Inc. grew its stake in shares of Generation Bio by 13.9% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 311,535 shares of the company’s stock worth $330,000 after acquiring an additional 38,090 shares in the last quarter. 95.22% of the stock is owned by institutional investors.

Generation Bio Stock Down 6.4 %

NASDAQ:GBIO traded down $0.03 during trading hours on Friday, reaching $0.43. The company had a trading volume of 558,689 shares, compared to its average volume of 257,951. The business’s 50-day simple moving average is $0.65 and its two-hundred day simple moving average is $1.39. Generation Bio has a twelve month low of $0.41 and a twelve month high of $4.65. The firm has a market cap of $28.67 million, a price-to-earnings ratio of -0.20 and a beta of 2.72.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). Generation Bio had a negative net margin of 782.86% and a negative return on equity of 104.85%. The firm had revenue of $4.19 million during the quarter, compared to analyst estimates of $2.92 million. As a group, equities analysts predict that Generation Bio will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

GBIO has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a research note on Friday, March 14th. Canaccord Genuity Group reissued a “buy” rating and issued a $9.00 price objective on shares of Generation Bio in a research note on Monday, March 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Generation Bio in a research note on Friday, March 14th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.